Clinical Trial Update: Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for etirinotecan pegol in refractory brain metastases, extensive-stage small cell lung cancer, recurrent NSCLC, metastatic breast cancer, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Extent Extents Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Tumors Metastatic to Brain

Drugs mentioned

• Etirinotecan Pegol (etirinotecan pegol)

Snippet

Sponsor: Joel Neal | Conditions: Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2019-09-10